Naatriumtsitraati

Naatriumtsitraati is a medication used to treat conditions related to incorrect heart rhythms, such as atrial fibrillation and atrial flutter. It comes in the form of an injectable or suppository. The active ingredient, sodium fusidate, is a cardioactive agent that belongs to the class of dihydropyridine calcium channel blockers.

The medication works by slowing the conduction of electrical impulses through the atria, which can help to regulate an abnormal heart rhythm. Its mechanism of action is to reduce the refractory period of the atria, thereby decreasing the likelihood of re-entrant rhythms.

Naatriumtsitraati is generally administered under medical supervision due to the potential for adverse effects. Common side effects include gastrointestinal disturbances, such as nausea and vomiting, and changes in cardiovascular function. In rare cases, more severe side effects can occur, including palpitations, bradycardia, and hypotension.

The medication's dosage and administration depend on the individual's medical condition and response to treatment. Injected doses are typically given in increments of 0.25 to 0.5 mg, with a maximum dose of 2 mg per injection. The duration of action can vary from several hours to a full day.

Naatriumtsitraati is metabolized through the liver, primarily by the cytochrome P450 enzyme system. Its efficacy and potential interaction with other medications can depend on individual variations in metabolic rate and enzyme expression. Due to the limited availability of clinical data, its long-term safety and effectiveness have not been comprehensively evaluated.